Company / R&D per Share
Monte Rosa Therapeutics, Inc. R&D per Share History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.64
FY2024
5-year range
$1.64 / $15.82
FY2020-FY2024
Trend
-24.0%
vs FY2023
Sector context
#119 of 208
Health Care
What the data says
At $1.64, Monte Rosa Therapeutics, Inc.'s r&d per share ranks #119 of 208 in the Health Care sector. Declined from $1.80 to $1.64 over the past 2 years.
Based on SEC 10-K filings.
1.64 in FY2024 with a 3-year CAGR of -10.4%.
Declined from $1.80 to $1.64 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -10.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#119 of 208 in Health CareTop 57% of 208This company $1.64 Sector average $28.82
▼
-94.3% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 24.0% year-over-year.
- Ranks #119 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.64 | -24.0% |
| FY2023 | $2.16 | +20.2% |
| FY2022 | $1.80 | -21.2% |
| FY2021 | $2.29 | -85.6% |
| FY2020 | $15.82 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026